Biofrontera Inc. (BFRI)
BFRI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1858685/000149315226011625/0001493152-26-011625-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BFRI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001858685 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $41.7M |
| Net income | -$10.5M |
| Operating income | -$11.3M |
| Net margin | -25.3% |
| Operating margin | -27.2% |
| Revenue growth | +11.7% |
| Cash | $6.4M |
| Total assets | $28.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Management believes that these conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these financial statements are issued." | 10-Q 2026-11-13 |
| Cash and burn | $4.7M cash; operating cash flow -$2.0M a quarter. | Report 2026-06-30 |
| Shares outstanding | 17,949,000 (2026-11-11); 11,648,323 a year earlier; 1,517,628 three years earlier. | Cover page 2026-11-11 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-01-07 |
| Delisting | 25-NSE filed | 25-NSE 2026-10-30 |
| Auditor | CBIZ CPAs P.C., Morristown, New Jersey, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $12.0M | -$604K | -$1.7M | $4.7M | $4.6M | $46.2M | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $10.1M | -$4.8M | -$70K | $6.3M | $4.7M | $43.2M | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $17.1M | $5.6M | -$2.4M | $6.4M | $4.6M | $41.7M | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | $7.0M | -$6.6M | -$3.8M | $3.4M | $4.5M | $37.2M | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $9.0M | -$5.3M | -$3.0M | $7.2M | $4.3M | $39.2M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $8.6M | -$4.2M | -$4.1M | $1.8M | $4.2M | $38.0M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $12.6M | -$1.4M | -$1.0M | $5.9M | $4.1M | $37.3M | 10-K 2026-03-19 |
| Q3 2024 2024-09-30 | $9.0M | -$5.7M | -$1.2M | $2.9M | No debt tags | $35.4M | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-1 | 2025-12-05 |
| Latest annual report | 10-K/A | 2026-07-22 |
| Latest quarterly / interim | 10-Q | 2026-11-13 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEF 14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 368 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -15.5% |
| 1 month | -21.5% |
| 3 months | -44.4% |
| Year to date | +22.8% |
| 1 year | -21.3% |
| From 52-week high | -56.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CLRB | Cellectar Biosciences Inc. | $1.01 | -11.40% | $10.1M |
| AEON | AEON Biopharma Inc. | $0.1407 | -8.04% | $10.1M |
| HIND | Vyome Holdings Inc. | $1.53 | -3.16% | $10.7M |
| PTN | Palatin Technologies Inc. | $6.13 | -1.69% | $10.9M |
| RADX | Radiopharm Theranostics Limited | $0.7676 | +1.00% | $11.1M |
| LEXX | Lexaria Bioscience Corp. | $4.41 | -0.68% | $9.3M |
| ASBP | Aspire-Lakewood Holdings Inc. | $8.06 | -5.29% | $11.3M |
| GDTC | CytoMed Therapeutics Limited | $0.7739 | -6.68% | $9.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier